Shijiazhuang Yiling Pharmaceutical Co., Ltd.
Symbol: 002603.SZ
SHZ
19.58
CNYMarket price today
12.0881
P/E Ratio
0.2763
PEG Ratio
32.71B
MRK Cap
- 0.03%
DIV Yield
Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603-SZ) Financial Statements
Balance Sheet
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 5918.12 | 2422.7 | 1050.5 | 1554 | |||||||||||||||
balance-sheet.row.short-term-investments | 960.06 | 518.4 | 55.3 | 217 | |||||||||||||||
balance-sheet.row.net-receivables | 11401.27 | 2699.6 | 2593.1 | 2102.4 | |||||||||||||||
balance-sheet.row.inventory | 9398.48 | 2021.8 | 1672.7 | 1580.3 | |||||||||||||||
balance-sheet.row.other-current-assets | 764.15 | 110.1 | 285.8 | 222.7 | |||||||||||||||
balance-sheet.row.total-current-assets | 27482.02 | 7254.2 | 5602.1 | 5459.4 | |||||||||||||||
balance-sheet.row.property-plant-equipment-net | 28847.51 | 6221.8 | 5745.5 | 4299.1 | |||||||||||||||
balance-sheet.row.goodwill | 458.41 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.intangible-assets | 1788.73 | 828 | 897.9 | 736.6 | |||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 2247.15 | 828 | 897.9 | 736.6 | |||||||||||||||
balance-sheet.row.long-term-investments | 6697.79 | 830.5 | -54.3 | -216 | |||||||||||||||
balance-sheet.row.tax-assets | 644.07 | 279.9 | 117 | 137.8 | |||||||||||||||
balance-sheet.row.other-non-current-assets | 3777.87 | 921.8 | 596.6 | 1075.3 | |||||||||||||||
balance-sheet.row.total-non-current-assets | 42214.38 | 9081.9 | 7302.7 | 6032.9 | |||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-assets | 69696.4 | 16336.1 | 12904.8 | 11492.3 | |||||||||||||||
balance-sheet.row.account-payables | 9244.98 | 2060.8 | 1621.2 | 1188.4 | |||||||||||||||
balance-sheet.row.short-term-debt | 5000.64 | 656.3 | 513.9 | 270.2 | |||||||||||||||
balance-sheet.row.tax-payables | 514.42 | 474 | 123.2 | 133.9 | |||||||||||||||
balance-sheet.row.long-term-debt-total | 2224.33 | 215.1 | 513 | 10.5 | |||||||||||||||
Deferred Revenue Non Current | 1093.93 | 335 | 357.8 | 328.1 | |||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 511.13 | - | - | - | |||||||||||||||
balance-sheet.row.other-current-liab | 969.93 | 1027.3 | 216.3 | 28.3 | |||||||||||||||
balance-sheet.row.total-non-current-liabilities | 3857.23 | 555.7 | 872.2 | 330.1 | |||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.capital-lease-obligations | 53.78 | 15 | 12.5 | 10.5 | |||||||||||||||
balance-sheet.row.total-liab | 22620.85 | 5405.8 | 3832.7 | 2569 | |||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.common-stock | 6682.82 | 1670.7 | 1670.7 | 1203.7 | |||||||||||||||
balance-sheet.row.retained-earnings | 26988.46 | 5989.2 | 4306.2 | 4324.4 | |||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 8525.75 | 989 | 808.9 | 640.9 | |||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 4566.63 | 2283.3 | 2283.3 | 2750.3 | |||||||||||||||
balance-sheet.row.total-stockholders-equity | 46763.66 | 10932.2 | 9069.1 | 8919.3 | |||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 69696.4 | 16336.1 | 12904.8 | 11492.3 | |||||||||||||||
balance-sheet.row.minority-interest | -40.48 | -1.9 | 3 | 4.1 | |||||||||||||||
balance-sheet.row.total-equity | 46723.18 | 10930.3 | 9072.2 | 8923.4 | |||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 69696.4 | - | - | - | |||||||||||||||
Total Investments | 7657.84 | 1348.9 | 1 | 1 | |||||||||||||||
balance-sheet.row.total-debt | 7252.82 | 871.4 | 1026.9 | 270.2 | |||||||||||||||
balance-sheet.row.net-debt | 2294.75 | -1032.8 | 31.6 | -1066.8 |
Cash Flow Statement
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 453.79 | 2356.8 | 1341.6 | 1214.9 | |||||||||||||||
cash-flows.row.depreciation-and-amortization | 18.64 | 451.5 | 362.9 | 268.2 | |||||||||||||||
cash-flows.row.deferred-income-tax | 0 | -158.7 | 20.1 | -67.7 | |||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 158.7 | -20.1 | 67.7 | |||||||||||||||
cash-flows.row.change-in-working-capital | 0 | 547.8 | -1309.7 | 24.8 | |||||||||||||||
cash-flows.row.account-receivables | 0 | -831.7 | -1280.3 | -668.7 | |||||||||||||||
cash-flows.row.inventory | 0 | -348 | -104.7 | -364.9 | |||||||||||||||
cash-flows.row.account-payables | 0 | 1886.2 | 55.1 | 1126.1 | |||||||||||||||
cash-flows.row.other-working-capital | 0 | -158.7 | 20.1 | -67.7 | |||||||||||||||
cash-flows.row.other-non-cash-items | -279.24 | 131.6 | 133.9 | 78.3 | |||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -97.94 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -266.96 | -214 | -673.6 | -1144.8 | |||||||||||||||
cash-flows.row.acquisitions-net | -675.79 | 0.4 | 2.4 | 1145.1 | |||||||||||||||
cash-flows.row.purchases-of-investments | -2677.83 | -3461.9 | -451 | -2853.3 | |||||||||||||||
cash-flows.row.sales-maturities-of-investments | 4232.64 | 1680.7 | 616.6 | 2957.6 | |||||||||||||||
cash-flows.row.other-investing-activites | 0.36 | 0 | -1.2 | -1144.8 | |||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 612.43 | -1994.8 | -506.8 | -1040.2 | |||||||||||||||
cash-flows.row.debt-repayment | -651.63 | -2200 | -1469.9 | -270 | |||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.dividends-paid | -1236.19 | -282.7 | -1220.1 | -244.1 | |||||||||||||||
cash-flows.row.other-financing-activites | 1548.01 | 1845.7 | 2387.9 | 490.8 | |||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -344.34 | -637 | -302.1 | -23.3 | |||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0.6 | 1.2 | -0.5 | -2 | |||||||||||||||
cash-flows.row.net-change-in-cash | 168.43 | 857.2 | -280.7 | 520.8 | |||||||||||||||
cash-flows.row.cash-at-end-of-period | 4775.1 | 1810.7 | 953.5 | 1234.2 | |||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 4606.67 | 953.5 | 1234.2 | 713.4 | |||||||||||||||
cash-flows.row.operating-cash-flow | -97.94 | 3487.7 | 528.7 | 1586.2 | |||||||||||||||
cash-flows.row.capital-expenditure | -266.96 | -214 | -673.6 | -1144.8 | |||||||||||||||
cash-flows.row.free-cash-flow | -364.9 | 3273.8 | -144.9 | 441.4 |
Income Statement Row
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 8836.76 | 12532.8 | 10116.8 | 8782.5 | |||||||||||||||
income-statement-row.row.cost-of-revenue | 4301.71 | 4540.6 | 3681 | 3118.4 | |||||||||||||||
income-statement-row.row.gross-profit | 4535.05 | 7992.3 | 6435.8 | 5664.1 | |||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.research-development | 860.36 | - | - | - | |||||||||||||||
income-statement-row.row.selling-general-administrative | 262.88 | - | - | - | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 1358.25 | - | - | - | |||||||||||||||
income-statement-row.row.other-expenses | -42.42 | 576.9 | 366.6 | 323 | |||||||||||||||
income-statement-row.row.operating-expenses | 3928.53 | 5025.8 | 4758.7 | 4179.2 | |||||||||||||||
income-statement-row.row.cost-and-expenses | 8230.24 | 9566.4 | 8439.7 | 7297.6 | |||||||||||||||
income-statement-row.row.interest-income | 22.9 | 12.9 | 20.4 | 7 | |||||||||||||||
income-statement-row.row.interest-expense | 42.41 | 33.8 | 34 | 3.8 | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 1358.25 | - | - | - | |||||||||||||||
income-statement-row.row.total-other-income-expensenet | -24.14 | -48.9 | -15.4 | -15.6 | |||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-operating-expenses | -42.42 | 576.9 | 366.6 | 323 | |||||||||||||||
income-statement-row.row.total-operating-expenses | -24.14 | -48.9 | -15.4 | -15.6 | |||||||||||||||
income-statement-row.row.interest-expense | 42.41 | 33.8 | 34 | 3.8 | |||||||||||||||
income-statement-row.row.depreciation-and-amortization | 124.37 | 546.1 | 448.6 | 329.5 | |||||||||||||||
income-statement-row.row.ebitda-caps | 747 | - | - | - | |||||||||||||||
income-statement-row.row.operating-income | 620.63 | 2829.6 | 1569.1 | 1438 | |||||||||||||||
income-statement-row.row.income-before-tax | 596.49 | 2780.6 | 1553.7 | 1422.5 | |||||||||||||||
income-statement-row.row.income-tax-expense | 151.7 | 423.8 | 212.1 | 207.5 | |||||||||||||||
income-statement-row.row.net-income | 453.79 | 2361.8 | 1343.9 | 1218.7 |
Frequently Asked Question
What is Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603.SZ) total assets?
Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603.SZ) total assets is 16336112689.000.
What is enterprise annual revenue?
The annual revenue is 4197033558.000.
What is firm profit margin?
Firm profit margin is 0.630.
What is company free cash flow?
The free cash flow is 0.986.
What is enterprise net profit margin?
The net profit margin is 0.206.
What is firm total revenue?
The total revenue is 0.243.
What is Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603.SZ) net profit (net income)?
The net profit (net income) is 2361804714.000.
What is firm total debt?
The total debt is 871449540.000.
What is operating expences number?
The operating expences are 5025828583.000.
What is company cash figure?
Enretprise cash is 1189759394.000.